Company profile: TRex Bio
1.1 - Company Overview
Company description
- Provider of a deep biology platform that maps human tissue regulatory T cell behavior to disease using high-resolution sequencing, computational biology and translational assays to identify targets, and developer of therapeutics for cancer, fibrotic and immune-mediated diseases, including TRB-061 (TNFR2 agonist; IND-enabling, FIH 2025), TRB-031/-041 (with Eli Lilly; lead optimization) and TRB-071/-081 (target ID/validation).
Products and services
- TRB-061: A TNFR2 agonist engineered to expand regulatory T cells and restore tissue homeostasis in inflamed tissues, IND-enabling, with first-in-human trials anticipated in early 2025
- Deep Biology Platform: A computationally integrated discovery system using high-resolution sequencing and translational biology assays to map human tissue regulatory T-cell behavior and identify novel therapeutic targets
- TRB-031: A therapeutic product engineered collaboratively with Eli Lilly targeting immune-mediated diseases, lead-optimization, currently progressing through design refinements consistent with its development stage
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to TRex Bio
Ventyx Biosciences
HQ: United States
Website
- Description: Provider of oral therapies for autoimmune, inflammatory and neurodegenerative disorders: VTX3232, a CNS-penetrant NLRP3 inhibitor for Parkinson’s, obesity, Alzheimer’s and multiple sclerosis; VTX2735, an NLRP3 inhibitor for systemic inflammation, initially cardiovascular; VTX002, an S1P1R modulator for ulcerative colitis; and VTX958, a TYK2 inhibitor for Crohn’s disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ventyx Biosciences company profile →
Padlock Therapeutics
HQ: United States
Website
- Description: Provider of medicines in development targeting protein-arginine deiminases (PADs), enzymes involved in the generation of autoantigens, inflammation, and immune complexes in autoimmune diseases. The company aims to explore the full biological and therapeutic footprint of protein deimination by PADs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Padlock Therapeutics company profile →
Encycle Therapeutics
HQ: Canada
Website
- Description: Provider of a platform technology for rapid synthesis of drug-like macrocycles and membrane-permeable nacellins, which have potential to target intracellular protein-protein interactions largely intractable to small molecule and biologic modulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Encycle Therapeutics company profile →
Santa Ana Bio
HQ: United States
Website
- Description: Provider of precision immunology drug development for autoimmune and inflammatory diseases, using single-cell genomics and advanced analytics to develop drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Santa Ana Bio company profile →
Fresh Tracks Therapeutics
HQ: United States
Website
- Description: Provider of pharmaceutical therapeutics for autoimmune, inflammatory, and debilitating diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fresh Tracks Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for TRex Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to TRex Bio
2.2 - Growth funds investing in similar companies to TRex Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for TRex Bio
4.2 - Public trading comparable groups for TRex Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →